An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
South Korean biotech company Peptron says it plans to start a Phase 1 clinical trial in Korea for a once-a-month formulation of semaglutide aimed at treating obesity. In plain terms, they want to test whether giving semaglutide once a month (instead of the current weekly shots) is safe and how the body handles it in a small group of people. This is an early-stage study mainly about safety and dosing, not a big proof that it will work better for weight loss. Semaglutide is the active ingredient in drugs people may have heard of, like Ozempic and Wegovy. It acts like a natural gut hormone that tells the brain you’re full and slows how fast your stomach empties, which helps reduce appetite and food intake. Current approved products use semaglutide as a once-weekly injection; Peptron is trying to change the formulation so the drug could be given once a month, which might be more convenient for patients. The planned Phase 1 trial is the first formal step in testing this new monthly version in humans. Phase 1 studies are usually small and focus on safety, how the drug moves through the body, and what dose is appropriate. This announcement doesn’t present new clinical results — it just says Peptron is seeking approval to run the trial. So we don’t yet know whether the monthly shot will work as well as the weekly one, how strong its effects on weight will be, or whether it will have the same side effects. If the monthly formulation does eventually prove safe and effective, it could matter to people who struggle with weekly injections or who prefer less frequent medical appointments. A once-monthly option might improve convenience and adherence (meaning people are more likely to stick with treatment), which can matter for long-term weight management. It could also influence how clinics schedule appointments and how insurers decide to cover treatment — but those are later-stage considerations that depend on trial success. There are important caveats. Phase 1 trials are small and not designed to show real-world effectiveness for weight loss. Semaglutide has known side effects, like nausea, vomiting, and possible effects on the pancreas or gallbladder in some people; any new formulation needs careful testing to make sure these risks aren’t increased. Also, Peptron still needs regulatory permission to run the trial and then much larger Phase 2 and 3 trials before any approval. Until those happen, this is an early development step, not an available new treatment. Bottom line: Peptron is taking the first human-testing step toward a once-monthly semaglutide shot for obesity, but it will be a long road before we know if it’s safe, effective, and better for patients than the existing weekly option.
Source: Chosunbiz